Comments Submitted to CMS by Bayer @ CRE Interactive Public Docket on CMS Competitive Bidding Rule

Comments Submitted to CMS by Bayer

1 comment

Bayer makes two key arguments in their comments: 1) maintaining the pharmacist-patient relationship is crucial to the health of diabetes patients; and 2) implementing competitive bidding for diabetes supplies would significantly undermine this relationship. Bayer cites two primary implications of harming the pharmacist-patient relationship: 1) reduced health quality for diabetic patients; and 2) increased expense to the federal government for treating more severe complications of diabetes
1 responses to “Comments Submitted to CMS by Bayer”
- Adm May 20th, 2009 at 13:56
  
  CRE has performed an initial examination of Bayer’s conclusions, including review of the studies cited by the company as supporting their conclusion regarding the importance of the pharmacist-patient relationship for diabetic patients. It appears that competitive bidding for diabetic supplies could undermine CMS’ health quality and fiscal responsibility goals. The next step should be to collect all relevant pharmacist-patient relationship data and analyze it within the context of CMS’ competitive bidding program. A detailed review of the Ashville Project study would be a good starting point for this work.
Leave a reply

Click here to cancel reply.

Name (not required for anonymous comments)

Mail (optional; will not be published)

Please Answer: *
8 + = 16